ISU Abxis Co., Ltd. (KOSDAQ:086890)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,135.00
-170.00 (-3.95%)
At close: May 15, 2026
Market Cap168.58B -10.4%
Revenue (ttm)56.67B -6.0%
Net Income-10.68B
EPSn/a
Shares Out40.77M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume313,359
Average Volume246,490
Open4,315.00
Previous Close4,305.00
Day's Range4,000.00 - 4,370.00
52-Week Range3,810.00 - 6,350.00
Beta0.61
RSI33.15
Earnings Daten/a

About ISU Abxis

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary inte... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2001
Employees 178
Stock Exchange KOSDAQ
Ticker Symbol 086890
Full Company Profile

Financial Performance

Financial Statements